Desloratadine 5 mg once daily improves quality of life in chronic idiopathic urticaria

S. Seidenari; A. Cirillo; S. Amoroso; M. L. Flori; P. Amerio; E. Ricciuti; G. A. Vena; E. Berardesca; C. Le Grazie; F. Giusti; R. Capizzi; M. A. Marino; C. Barbera; M. Ferraro; A. Cristaudo; E. Di Lella; G. Borroni; M. Mosca; S. Calvieri; A. G. Righetta; S. Chimenti; R. Barbati; A. Ciccarelli; C. Crosti; R. Calcaterra; E. Tolomio; O. De Pità; A. Provini; A. Finzi; P. Pigatto; M. Pellegrino; A. Molinu; A. Giomi; V. Griseta; A. Lerario; G. Leigheb; M. Bertero; R. Zuccoli; P. Lisi; L. Stingeni; K. Hansel; M. Lospalluti; M. L. Carriera; V. Serpenti; L. Muratore; A. Offidani; O. Simonetti; C. Simonini; C. Ortolani; J. W. Schroder; G. Vighi; F. Pezzuto; A. Pio; F. Ricciuti; L. Viola; P. Santoianni; G. Lembo; G. Moffa; E. Sbano; V. Altamura; Brindisi C. Troise; D. Bignardi; S. Voltolini; A. Tulli; A. De Benedetto; P. Toto; C. Varotti; T. Bianchi; G. A. Vena; N. Cassano; L. Zichichi; V. Maltese

Desloratadine 5 mg once daily improves quality of life in chronic idiopathic urticaria

S. Seidenari, A. Cirillo, S. Amoroso, M. L. Flori, P. Amerio, E. Ricciuti, G. A. Vena, E. Berardesca, C. Le Grazie, F. Giusti, R. Capizzi, M. A. Marino, C. Barbera, M. Ferraro, A. Cristaudo, E. Di Lella, G. Borroni, M. Mosca, S. Calvieri, A. G. RighettaS. Chimenti, R. Barbati, A. Ciccarelli, C. Crosti, R. Calcaterra, E. Tolomio, O. De Pità, A. Provini, A. Finzi, P. Pigatto, M. Pellegrino, A. Molinu, A. Giomi, V. Griseta, A. Lerario, G. Leigheb, M. Bertero, R. Zuccoli, P. Lisi, L. Stingeni, K. Hansel, M. Lospalluti, M. L. Carriera, V. Serpenti, L. Muratore, A. Offidani, O. Simonetti, C. Simonini, C. Ortolani, J. W. Schroder, G. Vighi, F. Pezzuto, A. Pio, F. Ricciuti, L. Viola, P. Santoianni, G. Lembo, G. Moffa, E. Sbano, V. Altamura, Brindisi C. Troise, D. Bignardi, S. Voltolini, A. Tulli, A. De Benedetto, P. Toto, C. Varotti, T. Bianchi, G. A. Vena, N. Cassano, L. Zichichi, V. Maltese

Research output: Contribution to journal › Article › peer-review

Abstract

Aim. Desloratadine (DL) is an effective treatment for chronic idiopathic urticaria (CIU) symptoms, but there is little information about its impact on patients' perceived general wellbeing. The primary objective was to measure the effect of DL on the quality of life (QoL) of CIU patients, using the Dermatology Life Quality Index (DLQI). Secondary objectives were: evaluation of the effects of DL on pruritus and number of hives, sleep and daily activities, overall CIU condition, and assessment of therapeutic response. Safety and tolerability of DL were also evaluated. Methods. Two-hundred and fifty-five patients, aged 18-79 years and with moderate to severe CIU, were treated with DL 5 mg once daily for 28 days. Patients recorded signs and symptoms scores daily, and completed the DLQI questionnaire at baseline and on treatment days 7, 14, 21 and 28. Patients and investigators jointly evaluated overall CIU condition and therapeutic response at days 14 and 28. Results. After 28 days of treatment, DL significantly reduced mean overall DLQI score from 9.4 (±5.4) at baseline to 3 (±4.1) (-66.1%; P

Original language	English
Pages (from-to)	207-214
Number of pages	8
Journal	Giornale Italiano di Dermatologia e Venereologia
Volume	141
Issue number	3
Publication status	Published - 2006

Keywords

Antihistamines
Chronic idiopathic urticaria
Dermatology life quality index (DLQI)
Desloratadine
Quality of life

ASJC Scopus subject areas

Dermatology

Cite this

Seidenari, S., Cirillo, A., Amoroso, S., Flori, M. L., Amerio, P., Ricciuti, E., Vena, G. A., Berardesca, E., Le Grazie, C., Giusti, F., Capizzi, R., Marino, M. A., Barbera, C., Ferraro, M., Cristaudo, A., Di Lella, E., Borroni, G., Mosca, M., Calvieri, S., ... Maltese, V. (2006). Desloratadine 5 mg once daily improves quality of life in chronic idiopathic urticaria. Giornale Italiano di Dermatologia e Venereologia, 141(3), 207-214.

Seidenari, S, Cirillo, A, Amoroso, S, Flori, ML, Amerio, P, Ricciuti, E, Vena, GA, Berardesca, E, Le Grazie, C, Giusti, F, Capizzi, R, Marino, MA, Barbera, C, Ferraro, M, Cristaudo, A, Di Lella, E, Borroni, G, Mosca, M, Calvieri, S, Righetta, AG, Chimenti, S, Barbati, R, Ciccarelli, A, Crosti, C, Calcaterra, R, Tolomio, E, De Pità, O, Provini, A, Finzi, A, Pigatto, P, Pellegrino, M, Molinu, A, Giomi, A, Griseta, V, Lerario, A, Leigheb, G, Bertero, M, Zuccoli, R, Lisi, P, Stingeni, L, Hansel, K, Lospalluti, M, Carriera, ML, Serpenti, V, Muratore, L, Offidani, A, Simonetti, O, Simonini, C, Ortolani, C, Schroder, JW, Vighi, G, Pezzuto, F, Pio, A, Ricciuti, F, Viola, L, Santoianni, P, Lembo, G, Moffa, G, Sbano, E, Altamura, V, Troise, BC, Bignardi, D, Voltolini, S, Tulli, A, De Benedetto, A, Toto, P, Varotti, C, Bianchi, T, Vena, GA, Cassano, N, Zichichi, L & Maltese, V 2006, 'Desloratadine 5 mg once daily improves quality of life in chronic idiopathic urticaria', Giornale Italiano di Dermatologia e Venereologia, vol. 141, no. 3, pp. 207-214.

@article{f76c80172ebd4b0199f364f9683c144f,

title = "Desloratadine 5 mg once daily improves quality of life in chronic idiopathic urticaria",

abstract = "Aim. Desloratadine (DL) is an effective treatment for chronic idiopathic urticaria (CIU) symptoms, but there is little information about its impact on patients' perceived general wellbeing. The primary objective was to measure the effect of DL on the quality of life (QoL) of CIU patients, using the Dermatology Life Quality Index (DLQI). Secondary objectives were: evaluation of the effects of DL on pruritus and number of hives, sleep and daily activities, overall CIU condition, and assessment of therapeutic response. Safety and tolerability of DL were also evaluated. Methods. Two-hundred and fifty-five patients, aged 18-79 years and with moderate to severe CIU, were treated with DL 5 mg once daily for 28 days. Patients recorded signs and symptoms scores daily, and completed the DLQI questionnaire at baseline and on treatment days 7, 14, 21 and 28. Patients and investigators jointly evaluated overall CIU condition and therapeutic response at days 14 and 28. Results. After 28 days of treatment, DL significantly reduced mean overall DLQI score from 9.4 (±5.4) at baseline to 3 (±4.1) (-66.1%; P",

keywords = "Antihistamines, Chronic idiopathic urticaria, Dermatology life quality index (DLQI), Desloratadine, Quality of life",

author = "S. Seidenari and A. Cirillo and S. Amoroso and Flori, {M. L.} and P. Amerio and E. Ricciuti and Vena, {G. A.} and E. Berardesca and {Le Grazie}, C. and F. Giusti and R. Capizzi and Marino, {M. A.} and C. Barbera and M. Ferraro and A. Cristaudo and {Di Lella}, E. and G. Borroni and M. Mosca and S. Calvieri and Righetta, {A. G.} and S. Chimenti and R. Barbati and A. Ciccarelli and C. Crosti and R. Calcaterra and E. Tolomio and {De Pit{\`a}}, O. and A. Provini and A. Finzi and P. Pigatto and M. Pellegrino and A. Molinu and A. Giomi and V. Griseta and A. Lerario and G. Leigheb and M. Bertero and R. Zuccoli and P. Lisi and L. Stingeni and K. Hansel and M. Lospalluti and Carriera, {M. L.} and V. Serpenti and L. Muratore and A. Offidani and O. Simonetti and C. Simonini and C. Ortolani and Schroder, {J. W.} and G. Vighi and F. Pezzuto and A. Pio and F. Ricciuti and L. Viola and P. Santoianni and G. Lembo and G. Moffa and E. Sbano and V. Altamura and Troise, {Brindisi C.} and D. Bignardi and S. Voltolini and A. Tulli and {De Benedetto}, A. and P. Toto and C. Varotti and T. Bianchi and Vena, {G. A.} and N. Cassano and L. Zichichi and V. Maltese",

year = "2006",

language = "English",

volume = "141",

pages = "207--214",

journal = "Minerva dermatologica",

issn = "0392-0488",

publisher = "Edizioni Minerva Medica S.p.A.",

number = "3",

}

TY - JOUR

T1 - Desloratadine 5 mg once daily improves quality of life in chronic idiopathic urticaria

AU - Seidenari, S.

AU - Cirillo, A.

AU - Amoroso, S.

AU - Flori, M. L.

AU - Amerio, P.

AU - Ricciuti, E.

AU - Vena, G. A.

AU - Berardesca, E.

AU - Le Grazie, C.

AU - Giusti, F.

AU - Capizzi, R.

AU - Marino, M. A.

AU - Barbera, C.

AU - Ferraro, M.

AU - Cristaudo, A.

AU - Di Lella, E.

AU - Borroni, G.

AU - Mosca, M.

AU - Calvieri, S.

AU - Righetta, A. G.

AU - Chimenti, S.

AU - Barbati, R.

AU - Ciccarelli, A.

AU - Crosti, C.

AU - Calcaterra, R.

AU - Tolomio, E.

AU - De Pità, O.

AU - Provini, A.

AU - Finzi, A.

AU - Pigatto, P.

AU - Pellegrino, M.

AU - Molinu, A.

AU - Giomi, A.

AU - Griseta, V.

AU - Lerario, A.

AU - Leigheb, G.

AU - Bertero, M.

AU - Zuccoli, R.

AU - Lisi, P.

AU - Stingeni, L.

AU - Hansel, K.

AU - Lospalluti, M.

AU - Carriera, M. L.

AU - Serpenti, V.

AU - Muratore, L.

AU - Offidani, A.

AU - Simonetti, O.

AU - Simonini, C.

AU - Ortolani, C.

AU - Schroder, J. W.

AU - Vighi, G.

AU - Pezzuto, F.

AU - Pio, A.

AU - Ricciuti, F.

AU - Viola, L.

AU - Santoianni, P.

AU - Lembo, G.

AU - Moffa, G.

AU - Sbano, E.

AU - Altamura, V.

AU - Troise, Brindisi C.

AU - Bignardi, D.

AU - Voltolini, S.

AU - Tulli, A.

AU - De Benedetto, A.

AU - Toto, P.

AU - Varotti, C.

AU - Bianchi, T.

AU - Vena, G. A.

AU - Cassano, N.

AU - Zichichi, L.

AU - Maltese, V.

PY - 2006

Y1 - 2006

N2 - Aim. Desloratadine (DL) is an effective treatment for chronic idiopathic urticaria (CIU) symptoms, but there is little information about its impact on patients' perceived general wellbeing. The primary objective was to measure the effect of DL on the quality of life (QoL) of CIU patients, using the Dermatology Life Quality Index (DLQI). Secondary objectives were: evaluation of the effects of DL on pruritus and number of hives, sleep and daily activities, overall CIU condition, and assessment of therapeutic response. Safety and tolerability of DL were also evaluated. Methods. Two-hundred and fifty-five patients, aged 18-79 years and with moderate to severe CIU, were treated with DL 5 mg once daily for 28 days. Patients recorded signs and symptoms scores daily, and completed the DLQI questionnaire at baseline and on treatment days 7, 14, 21 and 28. Patients and investigators jointly evaluated overall CIU condition and therapeutic response at days 14 and 28. Results. After 28 days of treatment, DL significantly reduced mean overall DLQI score from 9.4 (±5.4) at baseline to 3 (±4.1) (-66.1%; P

AB - Aim. Desloratadine (DL) is an effective treatment for chronic idiopathic urticaria (CIU) symptoms, but there is little information about its impact on patients' perceived general wellbeing. The primary objective was to measure the effect of DL on the quality of life (QoL) of CIU patients, using the Dermatology Life Quality Index (DLQI). Secondary objectives were: evaluation of the effects of DL on pruritus and number of hives, sleep and daily activities, overall CIU condition, and assessment of therapeutic response. Safety and tolerability of DL were also evaluated. Methods. Two-hundred and fifty-five patients, aged 18-79 years and with moderate to severe CIU, were treated with DL 5 mg once daily for 28 days. Patients recorded signs and symptoms scores daily, and completed the DLQI questionnaire at baseline and on treatment days 7, 14, 21 and 28. Patients and investigators jointly evaluated overall CIU condition and therapeutic response at days 14 and 28. Results. After 28 days of treatment, DL significantly reduced mean overall DLQI score from 9.4 (±5.4) at baseline to 3 (±4.1) (-66.1%; P

KW - Antihistamines

KW - Chronic idiopathic urticaria

KW - Dermatology life quality index (DLQI)

KW - Desloratadine

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=33745673161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745673161&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33745673161

SN - 0392-0488

VL - 141

SP - 207

EP - 214

JO - Minerva dermatologica

JF - Minerva dermatologica

IS - 3

ER -

Desloratadine 5 mg once daily improves quality of life in chronic idiopathic urticaria

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this